Angel H. Roffo Oncology Institute, Mohs Surgery Unit, Head and Neck Department, Alexander Fleming Institute, Skin Cancer Oncology, 1180 Cramer St., CABA (ZIP 1426), Buenos Aires, Argentina.
Angel H. Roffo Oncology Institute, Mohs Surgery Unit, Head and Neck Department, Alexander Fleming Institute, Skin Cancer Oncology, 1180 Cramer St., CABA (ZIP 1426), Buenos Aires, Argentina.
J Plast Reconstr Aesthet Surg. 2021 Nov;74(11):2999-3007. doi: 10.1016/j.bjps.2021.03.060. Epub 2021 Apr 8.
Squamous cell carcinoma of the ear (SCC-E) shows high rates of local recurrence (LR) and lymph node metastases (NM). SCC-E is the leading cause of death from nonmelanoma skin cancer.
To determine the LR and NM rates and survival after Mohs micrographic surgery (MMS).
We treated 170 invasive SCC-E with MMS with a mean follow up of 48 months. Mean age was 76 years, 93.2% were male patients, mean size: 1.5 cm, and 61.8% of the tumours were well differentiated.
We observed 5 LRs, 2 locoregional recurrences, and 16 NMs in 23 patients. LR and NM rates were 4.1% and 10.6%, respectively. Only 3/25 recurrences occurred after 2 years of follow up. We observed 1(0.6%) distant metastasis (DM) in a patient who also presented LR + NM. Six out of seven cases with LR and 8/18 with NM died of disease, regardless of aggressive surgical rescue with or without adjuvant radiotherapy. Five-year overall survival, disease-free survival, and disease-specific survival were 81%, 82.6%, and 89.7%, respectively.
Undeniably, the outcome in SCC-E is determined by locoregional control. DM are sporadic and rarely the cause of death. Systematic reviews and retrospective studies show a solid trend in favor of MMS vs surgical excision. The LR rate of this series (4.1%) is one of the lowest published to date with regard to SCC-E, and confirms this assertion. We observed 10.6% NMs according to other series that treated the whole spectrum of SCC-E. Almost 2/3 of patients with NMs die after therapeutic rescue. We believe that it is essential to identify prognostic factors to select patients for one of the following: close surveillance (ultrasonography) during the first 2 years after surgery, sentinel node biopsy, or elective treatment of the nodes (surgery or radiotherapy).
耳部鳞状细胞癌(SCC-E)具有较高的局部复发(LR)和淋巴结转移(NM)率。SCC-E 是导致非黑色素瘤皮肤癌死亡的主要原因。
确定 Mohs 显微外科手术(MMS)后的 LR 和 NM 发生率和生存率。
我们对 170 例接受 MMS 治疗的侵袭性 SCC-E 患者进行了治疗,平均随访时间为 48 个月。平均年龄为 76 岁,93.2%为男性患者,平均肿瘤大小为 1.5cm,61.8%的肿瘤分化良好。
我们观察到 23 例患者中有 5 例出现 LR,2 例出现局部复发,16 例出现 NM。LR 和 NM 发生率分别为 4.1%和 10.6%。仅 3 例复发发生在 2 年随访之后。我们观察到 1 例(0.6%)远处转移(DM)患者同时存在 LR+NM。6 例 LR 中有 6 例和 18 例 NM 中有 8 例因疾病死亡,无论是否进行积极的手术挽救治疗加或不加辅助放疗。5 年总生存率、无病生存率和疾病特异性生存率分别为 81%、82.6%和 89.7%。
毫无疑问,SCC-E 的结果取决于局部区域控制。DM 是散发性的,很少是死亡的原因。系统评价和回顾性研究显示,MMS 优于手术切除的趋势明显。本系列的 LR 率(4.1%)是迄今为止发表的关于 SCC-E 的最低比率之一,证实了这一说法。我们观察到 10.6%的 NM 发生率与治疗整个 SCC-E 范围的其他系列相似。近 2/3 的 NM 患者在治疗挽救后死亡。我们认为,确定预后因素以选择以下治疗方法至关重要:手术治疗后前 2 年进行密切监测(超声检查)、前哨淋巴结活检或选择性治疗淋巴结(手术或放疗)。